Major Price Cut by Eli Lilly: Humalog & Humulin Now More Affordable Eli Lilly will cut the list price of its most commonly prescribed insulin, Humalog and Humulin, by 70% in the fourth quarter this year. This price cut by Eli Lilly aims to make insulin more affordable for millions of diabetes patients, addressing concerns…
78% Price cut by Sanof Pharma: A Milestone for Diabetes Patients Major Price cut by Sanofi to Address Diabetes Care Sanofi Pharma, one of the largest global pharmaceutical companies, has announced a groundbreaking 78% reduction in insulin costs. This move aims to address the financial strain on diabetes patients, making lifesaving medication more accessible to…
75% Insulin price Cut by Novo Nordisk for insulin products in response to Public Pressure The announcement for substantial insulin price cut by Novo Nordisk n the list prices of several of its insulin products, with cuts of up to 75% set to take effect from January 2024. This move comes as part of the…
Breaking New Ground: Exenatide, a GLP-1 Receptor Agonist, Emerges as a Promising Therapy for Idiopathic Intracranial Hypertension Idiopathic intracranial hypertension (IIH), a rare neurological disorder marked by elevated intracranial pressure (ICP) of unknown origin, disproportionately affects young women with obesity. Its hallmark symptoms—blinding headaches, vision loss, tinnitus, and cognitive impairment—significantly impair quality of life. With…
Are There Alternatives to Ozempic in the USA to face drug shortage. Ozempic, an injectable medication primarily used to manage diabetes type 2, has seen a significant surge in demand in the USA, raising concerns about the supply chain. Manufactured by the pharmaceutical giant Novo Nordisk, it was approved by the FDA in 2017. The…
